• Edith M Heintjes, Anastassia Anastassopoulou, Josephina Kuiper, Aikaterini Bilitou, BeestFernie J A Penning-vanFJAP0000-0002-1906-9724PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands., HeringsRon M CRMC0000-0002-2561-8734PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands.Pharmacoepidemiology & Health Care Optimization, Department of Epidemiology & Data Science, Amsterdam Public Health Research Institute, Amsterdam UMC, Maarten J Postma, and J Wouter Jukema.
• PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands.
• Curr Med Res Opin. 2023 Jan 1; 39 (1): 1111-11.

ObjectiveTo describe treatment patterns, low-density lipoprotein cholesterol (LDL-C) levels and healthcare resource utilization (HCRU) in the Netherlands in 2018 of patients with hypercholesterolaemia or mixed dyslipidaemia at high or very high cardiovascular (CV) risk.MethodsFrom the PHARMO Database Network adult patients with a diagnosis or receiving lipid lowering therapy (LLT) between 2009 and 2018 were selected. Patients at high or very high CV risk according to 2016 ESC/EAS guidelines with recorded LDL-C levels who were treated with LLT or were characterized as statin intolerant in 2018 were included. LLT treatment patterns, LDL-C levels and HCRU (General Practitioner [GP] consultations and hospitalizations) were assessed.ResultsThe study population included 54,346 patients, of which 70% were at very high CV risk and 30% at high CV risk. The majority (93%) received statin monotherapy, mostly of moderate (73%) or high (15%) intensity. Only 3% received a combination of statin and ezetimibe. Statin intolerance, based on a treatment algorithm, was estimated at 3%. Average LDL-C decreased with LLT intensity. Overall, 74% reached LDL-C < 2.5 mmol/l and 34% <1.8 mmol/l with their current treatment, and 46% reached their LDL-C goal according to 2016 ESC/EAS guidelines. The highest rates of hospitalizations and GP consultations, including home visits, were recorded in patients with peripheral artery disease or polyvascular disease.ConclusionThe treatment of hypercholesterolaemia and mixed dyslipidaemia in patients at high or very high CV risk in the Netherlands was suboptimal in 2018. To further lower CV risk alternative treatment strategies using add-on therapies are needed.

27 keywords...

hide…